{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:58:16Z","timestamp":1783353496439,"version":"3.54.6"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.dld.2025.01.206","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:34:37Z","timestamp":1740728077000},"page":"1171-1179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Nonmedical switch of anti-TNF-\u03b1 biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-5808","authenticated-orcid":false,"given":"Giuseppe","family":"Privitera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Monastero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Melita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Schiavoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Barini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Barini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Tolusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Laterza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8334-7541","authenticated-orcid":false,"given":"Franco","family":"Scaldaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1572-0118","authenticated-orcid":false,"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2025.01.206_bib0001","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1080\/00365521.2023.2173988","article-title":"Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015\u20132020","volume":"58","author":"Jarlov Jensen","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2025.01.206_bib0002","first-page":"289","article-title":"The economic impact of the introduction of biosimilars in inflammatory bowel disease","volume":"11","author":"Severs","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.01.206_bib0003","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/rheumatology\/kex254","article-title":"Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results","volume":"56","author":"Smolen","year":"2017","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.dld.2025.01.206_bib0004","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/art.40336","article-title":"Versus reference Adalimumab in patients with moderate-to-severe rheumatoid arthritis","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.dld.2025.01.206_bib0005","first-page":"34","article-title":"Guidelines on evaluation of similar biotherapeutic products (SBPs)","author":"Health Organization","year":"2009","journal-title":"WHO Technic Report Series"},{"key":"10.1016\/j.dld.2025.01.206_bib0006","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2025.01.206_bib0007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40744-019-00190-7","article-title":"Nonmedical switching from originators to biosimilars: does the Nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology?","volume":"7","author":"Fleischmann","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.dld.2025.01.206_bib0008","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.dld.2019.02.004","article-title":"Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)","volume":"51","author":"Fiorino","year":"2019","journal-title":"Digest Liver Dis"},{"key":"10.1016\/j.dld.2025.01.206_bib0009","first-page":"690","article-title":"Biosimilar Infliximab in inflammatory bowel disease: outcomes of a managed switching programme","volume":"11","author":"Razanskaite","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.01.206_bib0010","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/apt.15223","article-title":"Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients","volume":"49","author":"Pouillon","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.01.206_bib0011","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/14712598.2020.1839045","article-title":"Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients","volume":"21","author":"Pugliese","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.dld.2025.01.206_bib0012","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjy114","article-title":"Ecco-esgar guideline for diagnostic assessment in ibd part 2: ibd scores and general principles and technical aspects","volume":"13","author":"Sturm","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.01.206_bib0013","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/apt.13001","article-title":"A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity","volume":"41","author":"Khanna","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.01.206_bib0014","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/apt.13408","article-title":"Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials","volume":"42","author":"Jairath","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.01.206_bib0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jgh.14496","article-title":"Validation of the inflammatory bowel disease disability index for self-report and development of an item-reduced version","volume":"34","author":"Paulides","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.01.206_bib0016","first-page":"1571","article-title":"The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's relapse prevention trial","volume":"91","author":"Irvine","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2025.01.206_bib0017","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","article-title":"Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system","volume":"13","author":"Yellen","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.dld.2025.01.206_bib0018","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.dld.2025.01.206_bib0019","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2307\/2136404","article-title":"A global measure of perceived stress","volume":"24","author":"Cohen","year":"1983","journal-title":"J Health Soc Behav"},{"key":"10.1016\/j.dld.2025.01.206_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08870449908407311","article-title":"The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication","volume":"14","author":"Horne","year":"1999","journal-title":"Psychol Health"},{"key":"10.1016\/j.dld.2025.01.206_bib0021","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/apt.13001","article-title":"A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity","volume":"41","author":"Khanna","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.01.206_bib0022","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.dld.2025.01.206_bib0023","first-page":"E27065","article-title":"Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis","volume":"100","author":"Yong","year":"2021","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.dld.2025.01.206_bib0024","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/jgh3.12068","article-title":"Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activity","volume":"2","author":"Zittan","year":"2018","journal-title":"JGH Open"},{"key":"10.1016\/j.dld.2025.01.206_bib0025","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cgh.2014.07.029","article-title":"Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab","volume":"13","author":"Yanai","year":"2015","journal-title":"Clinic Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.01.206_bib0026","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/MIB.0b013e3182813242","article-title":"Serum adalimumab concentration and clinical remission in patients with Crohn's Disease","volume":"19","author":"Chiu","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2025.01.206_bib0027","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1590\/s0004-2803.202000000-45","article-title":"Discontinuation rates following a switch from a reference to a biosimilar biologic in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"57","author":"Queiroz","year":"2020","journal-title":"Arq Gastroenterol"},{"key":"10.1016\/j.dld.2025.01.206_bib0028","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jpge.2015.11.004","article-title":"Anti-TNF withdrawal in inflammatory bowel disease","volume":"23","author":"Torres","year":"2016","journal-title":"GE Port J Gastroenterol"},{"key":"10.1016\/j.dld.2025.01.206_bib0029","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jcag\/gwad027","article-title":"An update on anti-TNF biosimilar switching\u2014Real-world clinical effectiveness and safety","volume":"7","author":"Meade","year":"2024","journal-title":"J Can Assoc Gastroenterol"},{"key":"10.1016\/j.dld.2025.01.206_bib0030","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40259-022-00548-4","article-title":"The nocebo effect in a non-medical switching program from originator to biosimilar Infliximab in inflammatory bowel disease","volume":"36","author":"Dutt","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.dld.2025.01.206_bib0031","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.dld.2023.06.022","article-title":"Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: a prospective observational study","volume":"56","author":"Wetwittayakhlang","year":"2024","journal-title":"Digest Liver Dis"},{"key":"10.1016\/j.dld.2025.01.206_bib0032","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14712598.2023.2211204","article-title":"Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey","volume":"23","author":"Sarl\u00f3s","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.dld.2025.01.206_bib0033","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/apt.15097","article-title":"Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease","volume":"49","author":"Shivaji","year":"2019","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825002221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825002221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:27:21Z","timestamp":1762554441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865825002221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1590865825002221"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.01.206","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonmedical switch of anti-TNF-\u03b1 biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.01.206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}